GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in allogeneic T-cell therapy. Its stock price represents a venture bet on the success of its revolutionary platform. The chart reflects high volatility and binary risks associated with clinical trial results.
Share prices of companies in the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases using donor cells. We have classified it in the "Pharma-Immune" segment. The chart below shows the overall dynamics of this cutting-edge cell therapy sector, which promises to revolutionize medicine but is fraught with significant risks.
Broad Market Index - GURU.Markets
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Atara shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ATRA - Daily change in the company's share price Atara Biotherapeutics
For Atara Biotherapeutics, a cell therapy company, daily price changes are a measure of extreme volatility. They reflect the market's reaction to research data and are a critical parameter in risk assessment formulas for innovative biotech companies.
Daily change in the price of a set of shares in a market segment - Pharma immune
For Atara Biotherapeutics, a cell therapy company, daily price changes are a measure of extreme volatility. They reflect the market's reaction to research data and are a critical parameter in risk assessment formulas for innovative biotech companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. The company's shares are driven by news of clinical successes. Their high volatility is part of a broader trend in which scientific breakthroughs shape market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Atara Biotherapeutics
For Atara Biotherapeutics, the year-end trend reflects its pioneering work in the field of "off-the-shelf" cell therapy. Its 12-month market cap is entirely dependent on regulatory approvals for its first drug for the treatment of post-transplant lymphoproliferative disorder (PTLD), which will serve as a fundamental validation of its scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
Atara Biotherapeutics, Inc. is a pioneer in the development of allogeneic (universal) T-cell immunotherapy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks associated with the development of this new class of drugs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Atara is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in allogeneic T-cell therapy. Its monthly performance is a barometer of its clinical and regulatory success. News about trial results, interactions with the FDA, and manufacturing progress are the main events driving strong share price movements.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Atara Biotherapeutics, Inc. is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of patients with cancer and autoimmune diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its cutting-edge platform, using T cells from healthy donors, could transform the treatment of serious diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Atara Biotherapeutics is a cell therapy company. Its shares don't follow the market, but rather move in leaps and bounds following the release of research data. The chart shows monthly price movements, which reflect investors' faith in its scientific platform rather than the state of the global economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Atara Biotherapeutics
Atara Biotherapeutics, a pioneer in allogeneic (donor) T-cell therapy, exhibits high volatility. Weekly stock performance is driven by news about clinical trials and regulatory decisions, reflecting the risks and enormous potential for breakthroughs in the treatment of cancer and autoimmune diseases.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy for cancer and autoimmune diseases. This chart shows how the market values its advanced yet complex technology relative to the sector, allowing us to separate its scientific risks from overall market volatility.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Atara Biotherapeutics is a biotech company developing cell therapy. Its shares exist in a world of their own, where research data is king. The chart shows that ATRA's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
ATRA - Market capitalization of the company Atara Biotherapeutics
Atara Biotherapeutics's stock price is a financial frontier in the field of allogeneic T-cell therapy. The market cap of this company, which develops "ready-to-use" cell therapies from donors, reflects the hopes for this breakthrough approach. Its volatility reflects the complex clinical trials and regulatory process for this new class of drugs.
ATRA - Share of the company's market capitalization Atara Biotherapeutics within the market segment - Pharma immune
Atara Biotherapeutics's stake in the immunology sector is a bet on revolutionary cell therapy. The company is a pioneer in allogeneic T-cell-based treatments. Its market share reflects the enormous potential of its platform for treating cancer and autoimmune diseases.
Market capitalization of the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell therapy from donors. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' hopes that "off-the-shelf" cell therapy will become more accessible and effective.
Market capitalization of all companies included in a broad market index - GURU.Markets
Atara Biotherapeutics is a pioneer in allogeneic T-cell therapy, which uses cells from healthy donors to treat cancer and autoimmune diseases. Its market capitalization is a bet on this platform. The chart below shows the economic weight of the off-the-shelf cell therapy sector.
Book value capitalization of the company, segment and market as a whole
ATRA - Book value capitalization of the company Atara Biotherapeutics
For Atara Biotherapeutics, a pioneer in cell therapy, book value is its manufacturing capacity and capital. The chart below shows the material and financial basis for its complex scientific business. Its dynamics reflect the massive investments in R&D and the establishment of a manufacturing base.
ATRA - Share of the company's book capitalization Atara Biotherapeutics within the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in T-cell-based cell therapy. Producing these complex "live" drugs requires unique and state-of-the-art facilities. The share price chart shows how the company is investing in building this sophisticated physical base.
Market segment balance sheet capitalization - Pharma immune
Atara Biotherapeutics is a pioneer in cell therapy. Unlike many "soft" biotechs, it has its own manufacturing facilities, making it more capital-intensive. The graph will show whether this vertical integration (science and manufacturing) is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Atara Biotherapeutics' assets include manufacturing facilities and a scientific platform for the development of allogeneic T-cell therapy, using healthy donor cells. The book value reflects the capital invested in this breakthrough technology, which has the potential to make cell therapy more accessible.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic (donor) T-cell therapy. Its balance sheet is a combination of cash and manufacturing capacity. Its market capitalization reflects its revolutionary platform and pipeline of drugs for the treatment of cancer and autoimmune diseases. The chart reflects the high risks and enormous potential of this emerging field of medicine.
Market to book capitalization ratio in a market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy. Its value stems from its unique scientific platform. The chart shows the vast gap between its market valuation and book value, reflecting investor confidence in the breakthrough nature of its technology.
Market to book capitalization ratio for the market as a whole
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell therapy, which does not require the use of the patient's own cells. The chart shows how the market values this potentially revolutionary approach to treating cancer and autoimmune diseases. Its high market capitalization is based on investor confidence in its scientific platform, not on its current assets.
Debts of the company, segment and market as a whole
ATRA - Company debts Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy. This is a capital-intensive field, requiring massive investments in R&D and the creation of sophisticated manufacturing facilities. This chart shows how the company is raising significant funds to bring its breakthrough technology to market.
Market segment debts - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. This "ready-to-use" cell therapy is a breakthrough. The chart illustrates the financial norms for the biotech sector, where companies are raising massive amounts of capital to finance their complex manufacturing processes and clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. This is one of the most advanced and expensive areas of medicine. This chart shows the proportion of debt funding for this breakthrough research, a critical indicator of financial risk for investors.
Market segment debt to market segment book capitalization - Pharma immune
Cell therapy development, Atara Biotherapeutics' specialty, is at the cutting edge of medicine, requiring massive investment. This chart shows how the biotech sector funds its most ambitious projects. It allows one to assess how capital-intensive Atara's business model, a pioneer in allogeneic T-cell therapy, is compared to the industry.
Debt to book value of all companies in the market
Atara Biotherapeutics develops cutting-edge cell therapy, one of the most complex and capital-intensive areas of biotech. This chart shows how high their debt load, required to fund their groundbreaking research, compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Atara Biotherapeutics
This chart shows the valuation of Atara Biotherapeutics, a pioneer in allogeneic T-cell immunotherapy. For a company developing a "off-the-shelf" cell therapy, its valuation is determined by investors' faith in its breakthrough scientific platform, not by current profits. The chart reflects expectations for clinical trial success.
P/E of the market segment - Pharma immune
This indicator represents the average valuation for the biotech sector in which Atara Biotherapeutics operates. It reflects the overall level of hope and expectation in the field of cell therapy. The chart serves as a barometer of investor confidence in the future of allogeneic immunotherapy.
P/E of the market as a whole
Atara Biotherapeutics is a pioneer in allogeneic T-cell therapy, developing ready-to-use donor-derived therapies for the treatment of cancer and autoimmune diseases. This chart shows market interest in cell therapy. It helps understand whether the market believes in the advantages of Atara's allogeneic approach over more complex autologous therapies and how they assess the risks of this cutting-edge technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy, creating ready-to-use drugs from donor cells for the treatment of cancer and autoimmune diseases. The company's future depends on the approval and success of its unique platform. This chart shows how investors view its innovative approach, which could make cell therapy more accessible.
%20P%2FE%20Atara%20Biotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Atara-Biotherapeutics&v=1772513605484 "Chart of the company's future (projected) P/E Atara Biotherapeutics")
Future (projected) P/E of the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in allogeneic (donor) T-cell immunotherapy for cancer and autoimmune diseases. This could make cell therapy more accessible. This chart reflects expectations for the biotech sector, helping to assess the market's confidence in this cutting-edge yet complex therapeutic platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513605500 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy, developing ready-to-use drugs for the treatment of cancer and autoimmune diseases. This chart of overall expectations shows the investor appetite for breakthrough biotechnologies. Market optimism and faith in science are critical to funding such complex and capital-intensive developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513605518 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy for cancer and autoimmune diseases. This chart shows the cost of developing "off-the-shelf" cell therapies. Profits depend on the approval and commercial success of its drugs, which can be manufactured in advance and stored for immediate use.
Profit of companies in the market segment - Pharma immune
Intrusion Inc. provides cybersecurity solutions focused on real-time threat identification. The company's profitability grows along with the volume of cyberattacks. This chart reflects the state of the sector, where the constant need to protect against new threats creates robust demand, but intense competition requires continuous innovation to maintain profitability.
Overall market profit
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell therapy, which uses cells from healthy donors to treat patients. The company targets cancer and autoimmune diseases. Its success depends on the results of clinical trials of this cutting-edge technology, which has the potential to change the paradigm of cell therapy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy (derived from a donor) for the treatment of cancer and autoimmune diseases. Its revenue forecast is dependent on the approval and commercialization of its drugs. This chart reflects analyst expectations for the future of cell therapy and Atara's breakthrough platform.
%20profit%20of%20the%20company%20Atara%20Biotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Atara-Biotherapeutics&v=1772513605611 "Graph of future (projected) profit of the company Atara Biotherapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy. The company uses T cells from healthy donors to treat cancer and autoimmune diseases. This chart shows profitability projections for the biotech sector. It reflects the enormous potential and technological challenges of off-the-shelf therapies that could transform medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513605633 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Atara Biotherapeutics develops cutting-edge T-cell immunotherapy-based treatments for patients with serious diseases. The company's success depends on the results of clinical trials. However, the overall economic environment, shown in this chart, affects the availability of capital to fund expensive research in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513605650 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy, developing ready-to-use drugs from healthy donor cells for the treatment of cancer and autoimmune diseases. The chart reflects investor valuation of its cutting-edge platform, which has the potential to significantly expand patient access to cell therapy but carries significant scientific risks.
P/S market segment - Pharma immune
Atara Biotherapeutics, Inc. is a pioneer in allogeneic T-cell immunotherapy, developing off-the-shelf therapeutics for the treatment of cancer and autoimmune diseases. Its future revenue depends on the success of this cutting-edge platform. This chart shows the average valuation in the sector, allowing one to assess how the market perceives the revenue potential of Atara's innovative technologies.
P/S of the market as a whole
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy, using cells from healthy donors to treat cancer and autoimmune diseases. This chart, showing average valuations, clearly demonstrates the significant premium investors place on the company's revenue potential, as it stands at the forefront of the cell therapy revolution.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. This chart reflects investors' confidence in the future success of its platform. The valuation is based on expectations for the approval and commercialization of its drugs, which could become affordable, off-the-shelf cell therapy.
%20P%2FS%20Atara%20Biotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Atara-Biotherapeutics&v=1772513605713 "The graph of the company's future (projected) P/S Atara Biotherapeutics")
Future (projected) P/S of the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy. The company develops ready-to-use therapies from healthy donor cells for the treatment of cancer and autoimmune diseases. The chart shows how the market estimates Atara's future sales, reflecting the enormous potential of its platform for creating affordable cell therapy.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513605745 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
This chart reflects the hopes surrounding cell therapy. Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell therapy, which uses cells from healthy donors and can be manufactured in advance. The potential of their "off-the-shelf" therapy for treating cancer and autoimmune diseases supports long-term investor optimism in this cutting-edge field.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513605763 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy. The company's revenue is generated by sales of its first approved drug, Ebvallo, in Europe. This chart shows the initial stages of commercialization of this advanced, off-the-shelf cell therapy for the treatment of rare diseases associated with the Epstein-Barr virus.
Sales of companies in the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy. The company develops ready-to-use cell therapies from donors for the treatment of cancer and autoimmune diseases. This chart represents the overall revenue in the immunology pharmaceutical sector. It highlights the cutting-edge field of cell therapy, where Atara strives to create a universal treatment.
Overall market sales
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy (ready-to-use cells from healthy donors) for the treatment of cancer and autoimmune diseases. The company's future depends on the success of its innovative platform. This overall economic climate influences investor willingness to finance cutting-edge and capital-intensive cell technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy (derived from healthy donors) for the treatment of cancer and autoimmune diseases. The company's future depends on the approval of its drugs. The chart shows speculative analyst forecasts, which are betting on a revolution in cell therapy and the success of its clinical programs.
%20sales%20of%20the%20company%20Atara%20Biotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Atara-Biotherapeutics&v=1772513605860 "Schedule of future (projected) sales of the company Atara Biotherapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy, which uses cells from healthy donors to treat cancer and autoimmune diseases. Success depends on the approval of this cutting-edge technology. This chart displays projected sales for the entire immunotherapy segment, highlighting overall growth expectations for cell therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513605888 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. The company is in late-stage development, and its future depends on regulatory approval. This overall economic climate impacts the investment climate, which will determine the funding for the commercial launch of its drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513605938 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy. This metric reflects the financial impact of its cutting-edge research. It demonstrates the investment in clinical trials and manufacturing required to commercialize its unique platform and bring new treatments to market.
Market segment marginality - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic (donor) T-cell therapy for the treatment of cancer and autoimmune diseases. Profitability depends on the success of this cutting-edge platform. This metric reflects its operational structure and significant investment in research compared to other cell therapy companies.
Market marginality as a whole
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy, using cells from healthy donors to treat patients with cancer and autoimmune diseases. Their success depends on clinical trials. This overall profitability curve doesn't affect their research, but it is important for investors to assess the risks and potential of the entire cell therapy sector.
Employees in the company, segment and market as a whole
Number of employees in the company Atara Biotherapeutics
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy that does not require individual production for each patient. This graph demonstrates the significant team size for a clinical company. The complexity of production and research requires a large team of scientists, engineers, and clinicians.
Share of the company's employees Atara Biotherapeutics within the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy. This chart shows the percentage of leading cell engineering scientists the company attracts. Unlike many others, the Atara team creates "ready-to-use" cell therapies from healthy donors, which has the potential to transform the industry.
Number of employees in the market segment - Pharma immune
Atara Biotherapeutics, Inc. is a pioneer in allogeneic T-cell immunotherapy for the treatment of cancer and autoimmune diseases. This chart shows overall employment in the immunology research sector. It illustrates the development of cutting-edge technology using T cells from healthy donors to create ready-to-use therapeutics.
Number of employees in the market as a whole
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell immunotherapy, creating ready-to-use drugs for the treatment of cancer and autoimmune diseases. It is a highly sophisticated biotech company. This chart illustrates the labor market, where such breakthrough companies are creating unique jobs for specialists in cell engineering, virology, and cryobiology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Atara Biotherapeutics (ATRA)
Atara Biotherapeutics is a pioneer in T-cell immunotherapy, developing ready-to-use (allogeneic) drugs for the treatment of cancer and autoimmune diseases. This chart is a prime example of biotech. The very high market capitalization per employee demonstrates that investors are investing in the potential of a unique scientific platform rather than current operating metrics.
%20of%20the%20company%20Atara%20Biotherapeutics%20(ATRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Atara-Biotherapeutics-ATRA&v=1772513606145 "Chart of market capitalization per employee (in thousands of dollars) of the company Atara Biotherapeutics (ATRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy. The company's entire value is captured by its revolutionary scientific platform. This metric demonstrates the enormous stake investors are placing in their technology. This high valuation reflects the belief that their approach to treating cancer and autoimmune diseases will become a new standard of medicine.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513606150 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell therapy (derived from a donor, not the patient). Its valuation is based on the potential of this complex but promising platform. The high market capitalization per employee reflects investors' confidence in the company's ability to overcome scientific and operational challenges.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513606176 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Atara Biotherapeutics (ATRA)
Atara Biotherapeutics is an R&D company and a pioneer in the field of allogeneic T-cell therapy (treatment from a "healthy" donor). This is a cutting-edge, but highly complex and expensive form of biotechnology. This graph shows the enormous investment (loss) per scientist working on developing this "off-the-shelf" cell therapy.
%20Chart%20Atara%20Biotherapeutics%20(ATRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Atara-Biotherapeutics-ATRA&v=1772513606191 "Company Profit Per Employee (in thousands of dollars) Chart Atara Biotherapeutics (ATRA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Atara Biotherapeutics is a pioneer in the development of allogeneic T-cell therapy. For a clinical-stage company, this metric is irrelevant. The graph represents the industry norm. If their complex technology is successful, Atara will be able to treat severe diseases, generating colossal profits with a relatively small staff, far exceeding the industry benchmark.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513606235 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Atara Biotherapeutics (ATRA) is a pioneer in allogeneic T-cell therapy (using T cells from a healthy donor). This is highly complex R&D in immuno-oncology. This chart illustrates the high cost of this research. The company's profit per employee is negative, as it invests hundreds of millions in clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513606243 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Atara Biotherapeutics (ATRA)
At Atara Biotherapeutics, a pioneer in the development of allogeneic T-cell therapy, this graph reflects progress in bringing innovative treatments to market. Revenue growth per employee will depend on the approval and commercial success of its drugs for the treatment of cancer and autoimmune diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Atara-Biotherapeutics-ATRA&v=1772513606263 "Sales chart per company employee Atara Biotherapeutics (ATRA)")
Sales per employee in the market segment - Pharma immune
Atara Biotherapeutics is developing off-the-shelf (allogeneic) T-cell therapies for the treatment of cancer and autoimmune diseases. This is a cutting-edge R&D company. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their research team is in advancing this complex therapy compared to competitors.
Sales per employee for the market as a whole
Atara Biotherapeutics (ATRA) is a biopharmaceutical company pioneering the development of allogeneic (universal) T-cell immunotherapy for the treatment of cancer and autoimmune diseases. This metric reflects their transition to commercialization. The increase in revenue per employee will reflect successful sales of their first approved drugs and the receipt of partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company Atara Biotherapeutics (ATRA)
Atara Biotherapeutics is a pioneer in allogeneic (off-the-shelf) T-cell therapy. Despite approval in Europe, the company has encountered difficulties in the US and has cut staff. This chart shows how many investors are betting that its complex and expensive technology will fail to achieve commercial success and will lose out to other treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Atara-Biotherapeutics-ATRA&v=1772513606333 "Short Shares Chart for the Company Atara Biotherapeutics (ATRA)")
Shares shorted by market segment - Pharma immune
Atara Biotherapeutics (ATRA) is a pioneer in the development of allogeneic (off-the-shelf) T-cell therapies for the treatment of cancer and autoimmune diseases. This chart shows the cumulative short position in the speculative cell therapy sector. It reflects the market's immense skepticism regarding the technical and clinical challenges of creating universal cell therapies.
Shares shorted by the overall market
Atara Biotherapeutics is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ATRA will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Atara Biotherapeutics (ATRA)
This chart shows the extreme volatility of Atara Biotherapeutics. The company is developing allogeneic T-cell therapy (treatment from the donor, not the patient). This is the holy grail of cell therapy. The approval of their drug (Ebvallo) in Europe triggered an "overheat" (above 70). However, delays in US approval or manufacturing difficulties immediately push the oscillator into "oversold" territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Atara-Biotherapeutics-ATRA&v=1772513606430 "RSI 14 indicator chart for the company's stock Atara Biotherapeutics (ATRA)")
RSI 14 Market Segment - Pharma immune
Atara (ATRA) is "CAR-T" 2.0 (Allo). They are pioneers of allogeneic (donor, off-the-shelf) T-cell therapy (for the treatment of EBV-associated diseases). The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It is vital to understand: is ATRA's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Atara Biotherapeutics (ATRA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATRA (Atara Biotherapeutics)
Atara Biotherapeutics is a pioneer in the development of allogeneic (donor-derived) T-cell therapy. Its key product (Ebvallo) is approved in Europe for the treatment of a rare type of lymphoma associated with the Epstein-Barr virus. This chart shows the average target price from analysts evaluating the commercialization of this R&D.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATRA-Atara-Biotherapeutics&v=1772513606505 "A chart showing analyst consensus forecasts for the expected stock price. ATRA (Atara Biotherapeutics)")
The difference between the consensus estimate and the actual stock price ATRA (Atara Biotherapeutics)
ATRA - Atara Biotherapeutics is a pioneer in allogeneic T-cell therapy. The company develops ready-to-use therapies from donor cells for the treatment of cancer and autoimmune diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in this sophisticated platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATRA-Atara-Biotherapeutics&v=1772513606531 "A chart showing the difference between the consensus forecast and the actual stock price. ATRA (Atara Biotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Atara Biotherapeutics (ATRA) is a pioneer in allogeneic T-cell therapy (derived from a donor, not a patient). Its drug, Ebvallo, has been approved in Europe. This chart shows general expectations for the immunopharma sector. It reflects whether experts believe in "off-the-shelf" cell therapy or consider it too complex.
Analysts' consensus forecast for the overall market share price
Atara Biotherapeutics is a biotech company pioneering the development of "off-the-shelf" (allogeneic) T-cell therapy for cancer and autoimmune diseases. This chart shows the overall risk appetite. For Atara, working in one of the most advanced and expensive areas of medicine, overall market optimism is critical to attracting the capital needed to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Atara Biotherapeutics
Atara (ATRA) is a pioneer in allogeneic (off-the-shelf) T-cell therapy. They don't use healthy cells, but rather harvest them from patients who have recovered from the Epstein-Barr virus. This graph represents their R&D bet. It measures their (complex) progress in commercializing their first drug (approved in the EU) and the market's confidence that their unique (but complex) platform will address other diseases.
AKIMA Market Segment Index - Pharma immune
Atara Biotherapeutics is a pioneer in allogeneic T-cell therapy. The company develops ready-to-use cell-based therapies for the treatment of cancer and autoimmune diseases. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Atara, with its breakthrough technology, compares to the average.
The AKIM Index for the overall market
Atara Biotherapeutics is a leader in allogeneic T-cell immunotherapy, developing treatments for diseases associated with the Epstein-Barr virus. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this cutting-edge scientific platform.
